Researchers at the Medical University of Vienna have taken a closer look at a previously largely unknown component of the immune system: the protein molecule TRAT1 (T Cell Receptor Associated ...

T cell therapy, which uses a patient's own immune cells to fight cancer, has emerged as a powerful way to treat lymphoma and other blood cancers. But researchers have struggled to adapt the treatment ...

In vivo CD19 CAR T-cell therapy showed promising results in a feasibility study of five patients with refractory systemic ...

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Early research has identified several antigens that could ...

Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic chimeric ...

Phase II Trial of Nivolumab Plus Doxorubicin, Vinblastine, Dacarbazine as Frontline Therapy in Older Adults With Hodgkin Lymphoma Colorectal cancer (CRC) remains a major global health burden, being ...

Researchers at the University of Oslo and Oslo University Hospital have developed a promising new immunotherapy targeting the CTNNB1 gene mutation associated with various aggressive cancers like lung ...

A special group of immune cells known as regulatory T cells, or Tregs for short, became an overnight sensation when a trio of ...

Moving Away From Standard Induction in Newly Diagnosed Acute Myeloid Leukemia As of April 2025, four CD19-directed chimeric antigen receptor (CAR)-T therapies and three CD20-targeting bispecific ...